Paion AG (FRA:PA8K)

Market Cap	313.88K +411.6%
Revenue (ttm)	14.81M -48.5%
Net Income	-19.86M
EPS	-2.79
Shares Out	7.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,329
Open	0.0550
Previous Close	0.0550
Day's Range	0.0500 - 0.0550
52-Week Range	0.0002 - 0.2300
Beta	4.14
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company’s lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distribu...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PA8K

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 5, 2026

Data Sources Report a data error